Regulus Therapeutics Inc (RGLS) 17.49 $RGLS
Late-Breaking Oral Presentation at The International Liver Congress(TM) (ILC 2015) Highlights RG-101's Potent, Durable and Pan-Genotypic Effects in Diverse HCV Population
PR Newswire - Sat Apr 25, 10:45AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today presented new data strengthening the profile of RG-101, a wholly-owned, GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122"
for the treatment of HCV, during an oral late-breaking session at ILC 2015 in Vienna, Austria. Extended follow-up results evaluating a single subcutaneous administration of either 2 mg/kg or 4 mg/kg of RG-101 as monotherapy in HCV patients with varied genotypes, liver fibrosis status and treatment history showed that 10/22 patients had HCV RNA levels below the limit of quantification ("BLOQ" at 12 weeks and 70 percent of those patients remained BLOQ at 20 weeks (7/10). In addition, the positive results that were previously reported from the completed clinical study of RG-101 were reviewed during the oral late-breaker.
RGLS: 17.49 (-0.80)
The Best Stock to Invest in Hep C
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 7:03AM CDT
Source: Gilead Sciences. The market for hepatitis C treatment is among the most lucrative for drugmakers, but it's also one of the most dynamically changing markets. Only 10 years ago, patients were treated with side effect-laden cocktails of drugs...
JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), RGLS: 17.49 (-0.80), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Critical Alerts For Inovio Pharmaceuticals, Perrigo Co., Weibo, Regulus Therapeutics and Qihoo 360 Technology Released By InvestorsObserver
PR Newswire - Thu Apr 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INO, PRGO, WB, RGLS and QIHU.
QIHU: 62.62 (+0.06), INO: 10.35 (-0.25), WB: 17.20 (+1.31), PRGO: 192.89 (-8.74), RGLS: 17.49 (-0.80)
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead
GILD: 103.69 (-1.52), TRGT: 2.43 (+0.04), JUNO: 56.66 (-1.06), RGLS: 17.49 (-0.80), ALKS: 62.26 (-1.19)
Leading Biotech Companies Seek Biologic Treatments for Rare Diseases Utilizing Viable Therapeutic Approach - Company Receives FDA Orphan Drug Designation for Bryostatin
PR Newswire - Thu Apr 09, 7:35AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Billions of dollars a year are being earmarked for new clinical studies and trials for the treatment of neurodevelopmental disorders as leading biotech companies race to identify treatments for genetic, cognitive, and neural levels for autism disorders. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), Alkermes plc (NASDAQ: ALKS), Regulus Therapeutics Inc. (NASDAQ: RGLS), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences Inc. (NASDAQ: GILD) and Abbot Laboratories (NYSE: ABT).
ABT: 48.32 (-0.14), INO: 10.35 (-0.25), GILD: 103.69 (-1.52), RGLS: 17.49 (-0.80), ALKS: 62.26 (-1.19)
Regulus to Present Late-Breaking, Expanded RG-101 Data Set for the Treatment of HCV at The International Liver Congress(TM) 2015 (ILC 2015)
PR Newswire - Thu Apr 09, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that multiple presentations related to RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122" for the treatment of chronic Hepatitis C Virus (HCV) infection, are scheduled for presentation at The International Liver Congress(TM) (ILC) 2015, April 22-26 in Vienna, Austria.
RGLS: 17.49 (-0.80)
Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 08, 1:53PM CDT
With first quarter earnings season yet to start, it was a relatively slow week for the biotech sector.
GILD: 103.69 (-1.52), TRGT: 2.43 (+0.04), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06), RGLS: 17.49 (-0.80), ALKS: 62.26 (-1.19), CELG: 118.71 (+2.62)
Why Regulus Therapeutics Inc. Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 08, 11:17AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Regulus Therapeutics ...
AZN: 71.79 (-1.34), RGLS: 17.49 (-0.80)
Stock Futures Trim Early Gains; Regulus, Tesla Jump, Shell Dips
at Investor's Business Daily - Wed Apr 08, 8:14AM CDT
Stock futures halved their already narrow gains ahead of Wednesday's start of trade. Dow futures remained 8.9 points above fair market value. Nasdaq 100 futures were ahead 2.1 points while S&P 500 futures clung to a fractional gain. Small caps were...
YZC: 10.26 (-0.06), TSLA: 218.43 (-0.17), ACH: 16.78 (+0.09), AZN: 71.79 (-1.34), RGLS: 17.49 (-0.80), ZNH: 50.72 (+1.37)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 8:12AM CDT
EYES: 13.35 (-0.35), PBR.A: 8.91 (+0.23), BALT: 1.61 (-0.04), LBIO: 12.34 (-0.08), RGLS: 17.49 (-0.80), ZEP: 19.88 (-0.03), WBAI: 17.20 (+0.16), PBR: 9.99 (+0.59), INO: 10.35 (-0.25), LGF: 32.43 (+0.49), CHL: 75.00 (+0.71), PSTR: 4.58 (-0.05), MPO: 1.09 (-0.07), CBMG: 29.51 (-1.85)
Regulus Therapeutics up 11% on AstraZeneca commitment on RG-125
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 6:51PM CDT
AZN: 71.79 (-1.34), RGLS: 17.49 (-0.80)
Regulus Soars As AstraZeneca Grabs NASH Drug Rights
at Investor's Business Daily - Tue Apr 07, 6:41PM CDT
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making...
GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ICPT: 283.20 (-2.22), ABBV: 66.07 (+1.82), RGLS: 17.49 (-0.80)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 4:36PM CDT
RCAP: 8.40 (-0.44), HLX: 16.36 (-0.32), EVR: 50.49 (+0.32), WG: 2.61 (-0.15), INFI: 14.54 (-0.11), RGLS: 17.49 (-0.80), PNR: 61.52 (+0.22), MRGE: 6.04 (+0.06), MTDR: 27.41 (-0.40), EPE: 13.42 (-0.06)
RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Selected as Clinical Candidate by AstraZeneca
PR Newswire - Tue Apr 07, 3:10PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107" for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 (AZD4076) is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5 million and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 (AZD4076) program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 (AZD4076) in humans by the end of 2015.
RGLS: 17.49 (-0.80)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), ZSPH: 40.97 (-1.90), RPTP: 10.81 (+0.10), OPK: 14.83 (+0.17), AMGN: 167.91 (-1.26), RGLS: 17.49 (-0.80), AMAG: 60.01 (-0.34), AKBA: 8.67 (-0.08), KERX: 11.41 (-0.32)
Regulus' RG-012 an Orphan Medicinal Product in Europe for genetic kidney disorder
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 9:47AM CDT
RGLS: 17.49 (-0.80)
Regulus Receives Orphan Medicinal Product Designation from the European Commission for RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome
PR Newswire - Wed Mar 25, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21" for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. In July 2014, the U.S. Food & Drug Administration granted orphan drug designation to RG-012 for the treatment of Alport syndrome.
RGLS: 17.49 (-0.80)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 401.71 (-28.57), ACT: 295.41 (-2.95), OVAS: 30.40 (-0.55), RGLS: 17.49 (-0.80), CTIC: 1.96 (+0.01), CELG: 118.71 (+2.62), BLCM: 27.88 (-0.46), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), RCPT: 169.88 (-1.26), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
FDA agrees to review Bristol-Myers' NDA for HCV drug
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 2:49PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), RGLS: 17.49 (-0.80), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Regulus Therapeutics (RGLS) Weak On High Volume Today
at The Street - Fri Mar 06, 9:02AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a weak on high relative volume candidate
RGLS: 17.49 (-0.80)
Late-Breaking Oral Presentation at The International Liver Congress(TM) (ILC 2015) Highlights RG-101's Potent, Durable and Pan-Genotypic Effects in Diverse HCV Population
PR Newswire - Sat Apr 25, 10:45AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today presented new data strengthening the profile of RG-101, a wholly-owned, GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122"
for the treatment of HCV, during an oral late-breaking session at ILC 2015 in Vienna, Austria. Extended follow-up results evaluating a single subcutaneous administration of either 2 mg/kg or 4 mg/kg of RG-101 as monotherapy in HCV patients with varied genotypes, liver fibrosis status and treatment history showed that 10/22 patients had HCV RNA levels below the limit of quantification ("BLOQ" at 12 weeks and 70 percent of those patients remained BLOQ at 20 weeks (7/10). In addition, the positive results that were previously reported from the completed clinical study of RG-101 were reviewed during the oral late-breaker. RGLS: 17.49 (-0.80)
The Best Stock to Invest in Hep C
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 7:03AM CDT
Source: Gilead Sciences. The market for hepatitis C treatment is among the most lucrative for drugmakers, but it's also one of the most dynamically changing markets. Only 10 years ago, patients were treated with side effect-laden cocktails of drugs...
JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), RGLS: 17.49 (-0.80), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Critical Alerts For Inovio Pharmaceuticals, Perrigo Co., Weibo, Regulus Therapeutics and Qihoo 360 Technology Released By InvestorsObserver
PR Newswire - Thu Apr 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INO, PRGO, WB, RGLS and QIHU.
QIHU: 62.62 (+0.06), INO: 10.35 (-0.25), WB: 17.20 (+1.31), PRGO: 192.89 (-8.74), RGLS: 17.49 (-0.80)
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead
GILD: 103.69 (-1.52), TRGT: 2.43 (+0.04), JUNO: 56.66 (-1.06), RGLS: 17.49 (-0.80), ALKS: 62.26 (-1.19)
Leading Biotech Companies Seek Biologic Treatments for Rare Diseases Utilizing Viable Therapeutic Approach - Company Receives FDA Orphan Drug Designation for Bryostatin
PR Newswire - Thu Apr 09, 7:35AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Billions of dollars a year are being earmarked for new clinical studies and trials for the treatment of neurodevelopmental disorders as leading biotech companies race to identify treatments for genetic, cognitive, and neural levels for autism disorders. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), Alkermes plc (NASDAQ: ALKS), Regulus Therapeutics Inc. (NASDAQ: RGLS), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences Inc. (NASDAQ: GILD) and Abbot Laboratories (NYSE: ABT).
ABT: 48.32 (-0.14), INO: 10.35 (-0.25), GILD: 103.69 (-1.52), RGLS: 17.49 (-0.80), ALKS: 62.26 (-1.19)
Regulus to Present Late-Breaking, Expanded RG-101 Data Set for the Treatment of HCV at The International Liver Congress(TM) 2015 (ILC 2015)
PR Newswire - Thu Apr 09, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that multiple presentations related to RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122"
for the treatment of chronic Hepatitis C Virus (HCV) infection, are scheduled for presentation at The International Liver Congress(TM) (ILC) 2015, April 22-26 in Vienna, Austria. RGLS: 17.49 (-0.80)
Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 08, 1:53PM CDT
With first quarter earnings season yet to start, it was a relatively slow week for the biotech sector.
GILD: 103.69 (-1.52), TRGT: 2.43 (+0.04), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06), RGLS: 17.49 (-0.80), ALKS: 62.26 (-1.19), CELG: 118.71 (+2.62)
Why Regulus Therapeutics Inc. Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 08, 11:17AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Regulus Therapeutics ...
AZN: 71.79 (-1.34), RGLS: 17.49 (-0.80)
Stock Futures Trim Early Gains; Regulus, Tesla Jump, Shell Dips
at Investor's Business Daily - Wed Apr 08, 8:14AM CDT
Stock futures halved their already narrow gains ahead of Wednesday's start of trade. Dow futures remained 8.9 points above fair market value. Nasdaq 100 futures were ahead 2.1 points while S&P 500 futures clung to a fractional gain. Small caps were...
YZC: 10.26 (-0.06), TSLA: 218.43 (-0.17), ACH: 16.78 (+0.09), AZN: 71.79 (-1.34), RGLS: 17.49 (-0.80), ZNH: 50.72 (+1.37)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 8:12AM CDT
EYES: 13.35 (-0.35), PBR.A: 8.91 (+0.23), BALT: 1.61 (-0.04), LBIO: 12.34 (-0.08), RGLS: 17.49 (-0.80), ZEP: 19.88 (-0.03), WBAI: 17.20 (+0.16), PBR: 9.99 (+0.59), INO: 10.35 (-0.25), LGF: 32.43 (+0.49), CHL: 75.00 (+0.71), PSTR: 4.58 (-0.05), MPO: 1.09 (-0.07), CBMG: 29.51 (-1.85)
Regulus Therapeutics up 11% on AstraZeneca commitment on RG-125
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 6:51PM CDT
AZN: 71.79 (-1.34), RGLS: 17.49 (-0.80)
Regulus Soars As AstraZeneca Grabs NASH Drug Rights
at Investor's Business Daily - Tue Apr 07, 6:41PM CDT
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making...
GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ICPT: 283.20 (-2.22), ABBV: 66.07 (+1.82), RGLS: 17.49 (-0.80)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 4:36PM CDT
RCAP: 8.40 (-0.44), HLX: 16.36 (-0.32), EVR: 50.49 (+0.32), WG: 2.61 (-0.15), INFI: 14.54 (-0.11), RGLS: 17.49 (-0.80), PNR: 61.52 (+0.22), MRGE: 6.04 (+0.06), MTDR: 27.41 (-0.40), EPE: 13.42 (-0.06)
RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Selected as Clinical Candidate by AstraZeneca
PR Newswire - Tue Apr 07, 3:10PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107"
for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 (AZD4076) is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5 million and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 (AZD4076) program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 (AZD4076) in humans by the end of 2015. RGLS: 17.49 (-0.80)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), ZSPH: 40.97 (-1.90), RPTP: 10.81 (+0.10), OPK: 14.83 (+0.17), AMGN: 167.91 (-1.26), RGLS: 17.49 (-0.80), AMAG: 60.01 (-0.34), AKBA: 8.67 (-0.08), KERX: 11.41 (-0.32)
Regulus' RG-012 an Orphan Medicinal Product in Europe for genetic kidney disorder
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 9:47AM CDT
RGLS: 17.49 (-0.80)
Regulus Receives Orphan Medicinal Product Designation from the European Commission for RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome
PR Newswire - Wed Mar 25, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"
for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. In July 2014, the U.S. Food & Drug Administration granted orphan drug designation to RG-012 for the treatment of Alport syndrome. RGLS: 17.49 (-0.80)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 401.71 (-28.57), ACT: 295.41 (-2.95), OVAS: 30.40 (-0.55), RGLS: 17.49 (-0.80), CTIC: 1.96 (+0.01), CELG: 118.71 (+2.62), BLCM: 27.88 (-0.46), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), RCPT: 169.88 (-1.26), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
FDA agrees to review Bristol-Myers' NDA for HCV drug
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 2:49PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), RGLS: 17.49 (-0.80), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Regulus Therapeutics (RGLS) Weak On High Volume Today
at The Street - Fri Mar 06, 9:02AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a weak on high relative volume candidate
RGLS: 17.49 (-0.80)
